



DISTRICT OF COLUMBIA

OFFICE OF THE STATE SUPERINTENDENT OF

EDUCATION

October 4, 2018

Dear Local Education Agency Allergy Management Liaison:

In June 2018, we drew attention to the national shortage of EpiPens® via a memo from Mylan. Given the shortage is ongoing, the Federal Drug Administration (FDA) has issued a statement via its website and has provided a [list of EpiPen® lot numbers](#) that are authorized for use beyond the manufacturer's original expiration date. We are encouraging you to review the statement from the FDA below and request that you check your EpiPens®' lot numbers and expiration dates to determine if you have EpiPens® with an extended expiration date. Please see FDA's statement below.

If your EpiPens® are included in this FDA extension, please log in to QuickBase and update your expiration dates no later than October 18, 2018.

Message from the FDA:

Extended Use Dates Provided by Pfizer

Extended use dates to assist with EpiPen® intermittent supply interruptions

[August 21, 2018] Due to the intermittent supply interruptions of EpiPen®, FDA is alerting health care professionals and patients of updated dates through which some EpiPens® and the authorized generic version, manufactured by Meridian Medical Technologies, a Pfizer company, may be used beyond the manufacturer's labeled expiration date. To help ensure patient safety, these products should have been — and should continue to be — stored as labeled.

Based on stability data provided by Pfizer and reviewed by FDA, the following extended use dates are supported for specific batches indicated in the tables [here](#). Patients that have the batch numbers below will be able to use them through the corresponding new use dates to help with supply. As data become available, this list can continue to expand.

FDA is not requiring or recommending that the identified batches in the following tables be relabeled with their new use dates. However, if replacement product becomes

available during the extension period, then the agency expects the lots in these tables will be replaced and properly disposed of as soon as possible.

Please see the recent [FDA in Brief](#) for more information, and contact CDER Drug Shortage Staff at drugshortages@fda.hhs.gov with questions regarding these tables.

You may access the FDA tables by [clicking this link](#).

The FDA oversees the development and distribution regulations for epinephrine via the EpiPen4Schools® Program. As you are aware, this program is a component of the Access to Epinephrine in Schools Act that ensures free auto-injectors are provided to our schools.

If you have questions regarding this or other matters related to the epi-pen program, please email OSSE.EPI@dc.gov. Please allow 48 hours for the team to follow up on any inquiries.

Sincerely,

OSSE Allergy Management Team